Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.40 |
| ▸ | DAO | P14920 | 2/20 | 0.38 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7034535 | 0.98 | TDP1 (0.50) | L3MBTL1POLBTDP1ALDH1A1KDM4E | |
| SCHEMBL10472839 | 0.98 | L3MBTL1 (0.50) | L3MBTL1POLBTDP1ALDH1A1KDM4E | |
| SCHEMBL27404772 | 0.88 | POLB (0.42) | L3MBTL1POLBTDP1ALDH1A1KDM4E | |
| SCHEMBL28971360 | 0.86 | ALDH1A1 (0.44) | L3MBTL1POLBTDP1ALDH1A1KDM4E | |
| SCHEMBL27430005 | 0.83 | L3MBTL1 (0.40) | L3MBTL1POLBTDP1ALDH1A1KDM4E | |
| SCHEMBL14125042 | 0.83 | KDM4E (0.41) | L3MBTL1POLBTDP1ALDH1A1KDM4E | |
| SCHEMBL3717041 | 0.83 | IKBKB (0.41) | L3MBTL1POLBTDP1ALDH1A1KDM4E | |
| SCHEMBL15751449 | 0.78 | POLB (0.35) | L3MBTL1POLBTDP1GAA | |
| SCHEMBL25467512 | 0.78 | GAA (0.41) | L3MBTL1POLBTDP1ALDH1A1KDM4E | |
| SCHEMBL2062392 | 0.78 | GAA (0.45) | L3MBTL1POLBTDP1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2556062-B1 | AMIDE DERIVATIVES OF AVENALUMIC ACID, PROCESS FOR PREPARING SAME AND COSMETIC COMPOSITIONS CONTAINING SAME | PROD CHIM AUXILIAIRES ET DE SYNTHESE (FR) | 2017-01-04 | — | — | EP | claimed |
| EP-2906566-B1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2016-08-24 | — | — | EP | claimed |
| EP-2214675-B1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH INC (US) | 2013-11-20 | — | — | EP | claimed |
| EP-2556062-A1 | AMIDE DERIVATIVES OF CINNAMIC, FERULIC AND AVENALUMIC SERIES, PROCESS FOR PREPARING SAME AND COSMETIC COMPOSITIONS CONTAINING SAME | Produits Chimiques Auxiliaires et de Synthese (FR) | 2013-02-13 | — | — | EP | claimed |
| WO-2011124844-A1 | AMIDE DERIVATIVES OF CINNAMIC, FERULIC AND AVENALUMIC SERIES, PROCESS FOR PREPARING SAME AND COSMETIC COMPOSITIONS CONTAINING SAME | PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) | 2011-10-13 | — | — | WO | claimed |
| WO-2011019680-A1 | PROCESS FOR PREPARING 4-METHYL-3-THIENYLAMINE HYDROCHLORIDE | SANOFI-AVENTIS U.S. LLC (US) | 2011-02-17 | — | — | WO | claimed |
| EP-2170872-B1 | PROCESS FOR THE PREPARATION OF THE N-(2-CHLORO-4-METHYL-3-THIENYL)-1H- BENZIMIDAZOL-2-AMINE HYDROCHLORIDE AND INTERMEDIATES THEREOF | SANOFI AVENTIS US LLC (US) | 2010-09-01 | — | — | EP | claimed |
| US-12522614-B2 | Topical phosphoinositide 3-kinase inhibitors | VENTHERA, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| EP-4514807-B1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250340570-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12421243-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | PRINTNET KERESKEDELMI ÉS SZOLGÁLTATÓ KFT. (HU) | 2025-09-23 | — | — | US | disclosed |
| WO-2025093589-A1 | HETEROARYL AMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-05-08 | — | — | WO | disclosed |
| WO-2025093590-A1 | HETEROARYL ESTER DERIVATIVES AS SODIUM CHANNEL INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-05-08 | — | — | WO | disclosed |
| US-5006535-A | Substituted heterocylic 4-aminoquinoline derivatives as gastric acid secretion inhibitors | SMITH KLINE & FRENCH LABORATORIES LTD. (GB) | 1991-04-09 | — | — | US | disclosed |
| EP-0336544-A1 | Heteroaryl 4-amino-3-acylquinoline derivatives and their use as inhibitors of gastric secretion | SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) | 1989-10-11 | — | — | EP | disclosed |
| US-4866065-A | ANTICONVULSANTS, ANXIOLYTIC AGENTS, HYPNOTICS, AND COGNITION ACTIVATORS | A/S FERROSAN (DK) | 1989-09-12 | — | — | US | disclosed |
| EP-0227431-A1 | Heterocyclic amides | BEECHAM GROUP PLC (GB) | 1987-07-01 | — | — | EP | disclosed |
| US-4659707-A | ANTIULCER, ANTISECRETORY, ANTIMUSCARINIC AND/OR ANTISPASMODIC AGENTS | DOMPE' FARMACEUTICI S.P.A. (IT) | 1987-04-21 | — | — | US | disclosed |
| EP-0213450-A2 | Aminoacyl derivatives of 4,9-dihydro-10H-pyrido[3,2-b]-thieno-[3,2-e][1,4]diazepinone and of 4,9-dihydro-10H-pyrido[3,2-b]-thieno[3,4-e][1,4]diazepinone, their preparation and pharmaceutical compositions containing them | DOMPE' FARMACEUTICI S.p.A. (IT) | 1987-03-11 | — | — | EP | disclosed |
| US-4139700-A | ACID-CATALYZED CYCLIZATION OF SULFAMOYL ACID OR ESTER | MONSANTO COMPANY (US) | 1979-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340570-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | RBM17, SF3A2, SMN1; SMN2 | L3MBTL1 542/4885POLB 397/4885TDP1 493/4885 |
| US-12421243-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | MYH2, MYLK2, MYO1B | L3MBTL1 4080/4885POLB 1490/4885TDP1 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.